Sobetirome has historical early human exposure data, but no established modern programme showing clinical benefit or approved treatment role. Weight-loss and other broad metabolic claims therefore remain unproven.
Still uncertain: Weight-loss benefit, long-term cardiovascular or disease outcomes, long-term safety or a current therapeutic regimen.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
Dyslipidaemia, metabolic and neurodegenerative research
Human evidence
Peer-reviewed reviews describe historical Phase I oral exposure with short-term lipid target engagement, including substantial LDL-C reductions, but a fully retrievable primary clinical report remains limited and development did not yield an approved therapy.
Regulatory status
No FDA/EMA-approved sobetirome medicine identified.
Main limitations
Weight-loss efficacy, long-term cardiovascular/disease outcomes, chronic safety or a current therapeutic regimen.
Safety
Thyroid-axis effects and long-term hepatic/cardiovascular/bone safety require clinical definition.
Evidence reviewed
2026-09-18
i
Peer-reviewed reviews describe historical Phase I oral exposure with short-term lipid target engagement, including substantial LDL-C reductions, but a fully retrievable primary clinical report remains limited and development did not yield an approved therapy.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Evidence rule: an outcome-specific evidence label is not a recommendation, a safety rating or an overall score for the compound.
Evidence synthesis
✓Human target engagement/lipid signal was observed in early development.
✓Mechanistic plausibility exists.
✓There is evidence of short-term lipid target engagement in humans.
Important limitations
!Primary full Phase I publication was not located in this pass; sample/dose details rely partly on development summaries.
!Thyromimetic safety/benefit differs fundamentally from incretin therapies.
!Primary full Phase I report is not readily retrievable; later development stopped.
Selected study & evidence records
Sobetirome Phase I development summary
2008 · Phase I human development programme summarized in peer-reviewed review · n=24
Peer-reviewed development reviews report Phase I human exposure and LDL-lowering pharmacology, with the programme not progressing to an approved therapy.
Thyroid-axis effects and long-term hepatic/cardiovascular/bone safety require clinical definition.
Short Phase I exposure cannot establish long-term cardiovascular, skeletal, thyroid-axis or other thyromimetic safety.
Technical details
Mechanism / biologySelective thyroid hormone receptor-beta agonism designed to affect lipid metabolism with fewer TR-alpha-mediated cardiac effects.
Route / formulation boundaryThis is not a peptide and should not be grouped with peptide pharmacology.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceHistorical Phase I human dosing reported; primary trial publication not located. Historical development records report single rising oral doses and 14-day multiple-dose regimens in healthy men. Present only as Phase I exposure data with source limitations.
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
2structured study records
3outcome records
7linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
